Therapy monitoring and follow-up of lung cancer are key to individualized patient treatment. Monitoring the tumor’s response allows a timely adaptation to the selected therapy. This is important when several therapeutic options are available, as is the case with lung cancer.
After completion of the therapy, a systematic follow-up for the early detection of lung cancer relapse should always be part of the patient’s workup and is described in the corresponding guidelines.
Computed Tomography & syngo.via
through functional examinations like tissue perfusion or iodine quantification SOMATOM CT systems enable an earlier assessment of tumor’s response in the lung or disease progression
syngo.via-based1 reading applications permit a standardized and efficient image analysis
longitudinal studies of the same patient are automatically registered, the trending of lesion size change is automatically visualized
structured reporting allows efficient communication across departments and disciplines
Positron Emission Tomography
early predictor of response
advanced system calibration of Biograph PET/CT systems helps ensure consistent quantitative accuracy across multiple time points
Small, 4 mm LSO crystals provide high sensitivity in detecting local and distant recurrences of lung carcinoma
syngo.via with EQ•PET helps reduce technology-induced variations and inter-reader variability by normalizing PET SUV values between different scanners and reconstruction methods
Continuous bed motion, made possible by FlowMotion™ technology supports precise disease characterization in therapy monitoring of lung cancer
comprehensive menu of oncology tests, e.g. general and specific tests to assess side-effects in the patient or tumor markers such as carcinoembryonic antigen (CEA)